CRISPR excites ambition. Just consider a few CRISPR applications: gene drives (showing promise as a way to prevent malaria); ex vivo and in vivo gene therapies (entering clinical trials); and ...

The type I CRISPR protein Cas3 works like Pac-Man, chomping away at a continuous stream of nucleotides with intrinsic activity for introducing targeted large deletions from a few hundred base pairs to ...

Researchers at Gladstone Institutes (CA, USA) have mapped the human immune response using next-generation CRISPR technology known as base editing. Using this tool, the team was able to identify ...

Vertex and CRISPR Therapeutics have taken a small step toward a landmark approval, securing European Medicines Agency (EMA) validation of the approval application for their CRISPR-Cas9 candidate. The ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on November 27, 2023, entitled, “The double-edge sword of CRISPR application for in vivo studies.” In ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

Sources stress the importance of careful drafting after an Australian court rejected the Korean company’s priority claims that were traced back to an unconventional manuscript A Federal Court of ...